Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Yamanouchi discloses Na+/H+ exchange inhibitors

May 30, 1997

Preliminary results from phase I trial of Nortran's RSD-921 reported

May 30, 1997

Use of labetalol in renal transplant patients discouraged

May 28, 1997

Clevidipine for controlling hypertension after CABG

May 27, 1997

ET antagonists disclosed by Merck KGaA

May 27, 1997

ETA antagonist effective against neointima formation in rabbit model

May 26, 1997

Y-26763 protects against ischemia/reperfusion injury in dog model

May 26, 1997

Pfizer sponsors large cardiovascular trial in U.K. and Scandinavia

May 26, 1997

Potent, nonpeptide ECE-1/NEP inhibitor discovered by Novartis

May 26, 1997

Mylan receives FDA approval of generic captopril/hydrochlorothiazide

May 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...